FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056959197> ?p ?o ?g. }

• W2056959197 endingPage "742" @default.
• W2056959197 startingPage "739" @default.
• W2056959197 abstract "Abstract Objective of the study was to test the efficacy, safety, and tolerability of two single doses of Epoetin alfa in patients with Friedreich's ataxia. Ten patients were treated subcutaneously with 600 IU/kg for the first dose, and 3 months later with 1200 IU/kg. Epoetin alfa had no acute effect on frataxin, whereas a delayed and sustained increase in frataxin was evident at 3 months after the first dose (+35%; P < 0.05), and up to 6 months after the second dose (+54%; P < 0.001). The treatment was well tolerated and did not affect hematocrit, cardiac function, and neurological scale. Single high dose of Epoetin alfa can produce a considerably larger and sustained effect when compared with low doses and repeated administration schemes previously adopted. In addition, no hemoglobin increase was observed, and none of our patients required phlebotomy, indicating lack of erythropoietic effect of single high dose of erythropoietin. © 2010 Movement Disorder Society" @default.
• W2056959197 created "2016-06-24" @default.
• W2056959197 creator A5016585696 @default.
• W2056959197 creator A5022886141 @default.
• W2056959197 creator A5027587292 @default.
• W2056959197 creator A5031570157 @default.
• W2056959197 creator A5049046612 @default.
• W2056959197 creator A5057864003 @default.
• W2056959197 creator A5058260855 @default.
• W2056959197 creator A5063611127 @default.
• W2056959197 creator A5068419990 @default.
• W2056959197 creator A5071384912 @default.
• W2056959197 creator A5074861019 @default.
• W2056959197 creator A5075593274 @default.
• W2056959197 creator A5087872474 @default.
• W2056959197 creator A5089308397 @default.
• W2056959197 date "2010-11-10" @default.
• W2056959197 modified "2023-10-10" @default.
• W2056959197 title "Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit" @default.
• W2056959197 cites W1531229638 @default.
• W2056959197 cites W1972791578 @default.
• W2056959197 cites W1978726693 @default.
• W2056959197 cites W2030699972 @default.
• W2056959197 cites W2043288745 @default.
• W2056959197 cites W2065083959 @default.
• W2056959197 cites W2082077613 @default.
• W2056959197 cites W2082490162 @default.
• W2056959197 cites W2083814934 @default.
• W2056959197 cites W2090939179 @default.
• W2056959197 cites W2095184629 @default.
• W2056959197 cites W2116374220 @default.
• W2056959197 cites W2123164720 @default.
• W2056959197 cites W2133155560 @default.
• W2056959197 cites W2150789570 @default.
• W2056959197 cites W2154254146 @default.
• W2056959197 cites W2158155007 @default.
• W2056959197 cites W2168176110 @default.
• W2056959197 cites W2168359248 @default.
• W2056959197 doi "https://doi.org/10.1002/mds.23435" @default.
• W2056959197 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21506154" @default.
• W2056959197 hasPublicationYear "2010" @default.
• W2056959197 type Work @default.
• W2056959197 sameAs 2056959197 @default.
• W2056959197 citedByCount "38" @default.
• W2056959197 countsByYear W20569591972012 @default.
• W2056959197 countsByYear W20569591972013 @default.
• W2056959197 countsByYear W20569591972014 @default.
• W2056959197 countsByYear W20569591972015 @default.
• W2056959197 countsByYear W20569591972016 @default.
• W2056959197 countsByYear W20569591972017 @default.
• W2056959197 countsByYear W20569591972018 @default.
• W2056959197 countsByYear W20569591972019 @default.
• W2056959197 countsByYear W20569591972020 @default.
• W2056959197 countsByYear W20569591972021 @default.
• W2056959197 countsByYear W20569591972022 @default.
• W2056959197 crossrefType "journal-article" @default.
• W2056959197 hasAuthorship W2056959197A5016585696 @default.
• W2056959197 hasAuthorship W2056959197A5022886141 @default.
• W2056959197 hasAuthorship W2056959197A5027587292 @default.
• W2056959197 hasAuthorship W2056959197A5031570157 @default.
• W2056959197 hasAuthorship W2056959197A5049046612 @default.
• W2056959197 hasAuthorship W2056959197A5057864003 @default.
• W2056959197 hasAuthorship W2056959197A5058260855 @default.
• W2056959197 hasAuthorship W2056959197A5063611127 @default.
• W2056959197 hasAuthorship W2056959197A5068419990 @default.
• W2056959197 hasAuthorship W2056959197A5071384912 @default.
• W2056959197 hasAuthorship W2056959197A5074861019 @default.
• W2056959197 hasAuthorship W2056959197A5075593274 @default.
• W2056959197 hasAuthorship W2056959197A5087872474 @default.
• W2056959197 hasAuthorship W2056959197A5089308397 @default.
• W2056959197 hasConcept C118552586 @default.
• W2056959197 hasConcept C126322002 @default.
• W2056959197 hasConcept C126894567 @default.
• W2056959197 hasConcept C141071460 @default.
• W2056959197 hasConcept C197934379 @default.
• W2056959197 hasConcept C22814914 @default.
• W2056959197 hasConcept C2776164570 @default.
• W2056959197 hasConcept C2777357209 @default.
• W2056959197 hasConcept C2778248108 @default.
• W2056959197 hasConcept C2778375690 @default.
• W2056959197 hasConcept C2778534260 @default.
• W2056959197 hasConcept C2779314966 @default.
• W2056959197 hasConcept C2779369046 @default.
• W2056959197 hasConcept C2780906641 @default.
• W2056959197 hasConcept C2780959883 @default.
• W2056959197 hasConcept C42219234 @default.
• W2056959197 hasConcept C71924100 @default.
• W2056959197 hasConcept C90924648 @default.
• W2056959197 hasConceptScore W2056959197C118552586 @default.
• W2056959197 hasConceptScore W2056959197C126322002 @default.
• W2056959197 hasConceptScore W2056959197C126894567 @default.
• W2056959197 hasConceptScore W2056959197C141071460 @default.
• W2056959197 hasConceptScore W2056959197C197934379 @default.
• W2056959197 hasConceptScore W2056959197C22814914 @default.
• W2056959197 hasConceptScore W2056959197C2776164570 @default.
• W2056959197 hasConceptScore W2056959197C2777357209 @default.
• W2056959197 hasConceptScore W2056959197C2778248108 @default.
• W2056959197 hasConceptScore W2056959197C2778375690 @default.

• next